Ann: Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA, page-95

Hi @Steini

Can you please clarify what you mean regarding mistakes I have made concerning efficacy?

My comments regarding the Hervaxx trial were that Hervaxx works, is safe, had a P value of 0.06, and 16 patients received a Hervaxx arm during the trial. All of these points I believe to be factual and correct.

My post was largely concerning the commercialisation prospects of Hervaxx and what paths forward Imugene has to reach a commercialisation outcome for Hervaxx. If you wish to disagree with me on that or have another opinion to put forward that is okay. I just don’t see the relevance to comparing other late-stage cancer trials to Imugene’s trial, the efficacy of said trial, and how that will impact a commercialisation outcome for Hervaxx other then what I have already said.

Commercialisation of Hervaxx will be dependent on strong outcomes resulting from NextHorrizion and NeoHorrizion trials. Which are 12 – 24 months away (first patient has yet to be dosed, albeit that now doesn’t appear too far away).

Personally I feel there is a very good chance Imugene will receive strong patient outcomes from their studies. And with a bit of luck on our side those results should only take 12 months to materialise. But there are always risks associated with investments.

*My opinions are not financial advice. Investing in the share market has inherit risks. Please do your own research before deciding if any investment is suitable to your own personal needs and goals.